Charles River Laboratories International, Inc. (NYSE:CRL) Holdings Reduced by CNB Bank

CNB Bank lessened its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 8.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,462 shares of the medical research company’s stock after selling 240 shares during the period. CNB Bank’s holdings in Charles River Laboratories International were worth $454,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Wellington Management Group LLP raised its stake in Charles River Laboratories International by 135,927.9% during the 3rd quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company’s stock valued at $736,819,000 after acquiring an additional 3,738,018 shares in the last quarter. Allspring Global Investments Holdings LLC increased its holdings in shares of Charles River Laboratories International by 40.7% during the third quarter. Allspring Global Investments Holdings LLC now owns 1,760,781 shares of the medical research company’s stock valued at $346,821,000 after purchasing an additional 509,163 shares during the period. Marshall Wace LLP raised its stake in shares of Charles River Laboratories International by 24.6% during the second quarter. Marshall Wace LLP now owns 825,905 shares of the medical research company’s stock valued at $170,615,000 after purchasing an additional 163,056 shares in the last quarter. 1832 Asset Management L.P. acquired a new stake in Charles River Laboratories International in the second quarter worth about $33,053,000. Finally, Earnest Partners LLC grew its position in Charles River Laboratories International by 12.4% in the 2nd quarter. Earnest Partners LLC now owns 1,004,486 shares of the medical research company’s stock valued at $207,507,000 after buying an additional 110,725 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Charles River Laboratories International Trading Up 0.4 %

Shares of NYSE CRL opened at $166.49 on Friday. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61. The firm has a market capitalization of $8.51 billion, a PE ratio of 20.86, a PEG ratio of 6.62 and a beta of 1.38. Charles River Laboratories International, Inc. has a one year low of $160.85 and a one year high of $275.00. The business has a 50-day moving average price of $191.67 and a two-hundred day moving average price of $198.72.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, beating analysts’ consensus estimates of $2.43 by $0.16. The business had revenue of $1.01 billion for the quarter, compared to analyst estimates of $975.99 million. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The firm’s revenue for the quarter was down 1.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.72 EPS. As a group, analysts predict that Charles River Laboratories International, Inc. will post 10.18 earnings per share for the current fiscal year.

Analysts Set New Price Targets

CRL has been the subject of a number of research analyst reports. Robert W. Baird reduced their price target on shares of Charles River Laboratories International from $191.00 to $190.00 and set a “neutral” rating for the company in a research note on Friday, September 20th. Redburn Atlantic assumed coverage on Charles River Laboratories International in a research note on Monday, October 14th. They set a “sell” rating and a $151.00 price target for the company. CLSA downgraded Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price objective on the stock. in a research note on Monday, November 18th. TD Cowen raised their target price on Charles River Laboratories International from $203.00 to $227.00 and gave the company a “hold” rating in a research note on Monday, November 11th. Finally, UBS Group reiterated a “neutral” rating and issued a $185.00 price target (down from $250.00) on shares of Charles River Laboratories International in a research report on Friday. Three research analysts have rated the stock with a sell rating, twelve have given a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $209.00.

Insiders Place Their Bets

In related news, Director Richard F. Wallman sold 6,621 shares of the business’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the transaction, the director now directly owns 12,386 shares in the company, valued at $2,676,862.32. The trade was a 34.83 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 1.30% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).